HUTCHMED (China) Ltd (STU:H7T1)
€ 15.7 0 (0%) Market Cap: 2.68 Bil Enterprise Value: 2.01 Bil PE Ratio: 0 PB Ratio: 4.10 GF Score: 70/100

Full Year 2018 Hutchison China MediTech Ltd Earnings Call Transcript

Mar 11, 2019 / 09:00AM GMT
Christian Hogg
Hutchison China MediTech Limited - CEO & Executive Director

Okay. All right. Well, 9:00. So thank you, everybody, for attending today the Hutchison China MediTech 2018 Results Presentation. As always, it's a very detailed presentation, but I'm going to just go through the slides and touch on the main points. The disclaimer, as always.

So starting off with the financial results. Before I go diving into the actual numbers for the year, I thought I'd stop on this slide for a moment, Slide #3 -- 4 rather. We really have 3 core areas of our focus these days as we strive to build a science-based or science-focused global biopharmaceutical company off of our base in China. The 3 areas we're focused on are: global innovation, China oncology and obviously our existing China business.

Global innovation these days is all about bringing our small molecule targeted therapies to development in the global market. We, today, have 5 assets that we are either in development outside of China or about to start development out of China. So more and more, this is us trying to maximize the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot